News Conference News ESC 2025 High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors Caitlin E. Cox August 29, 2025
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Conference News ESC 2020 VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban L.A. McKeown September 03, 2020
News Conference News ESC 2019 Young MI Patients’ Ischemic Risk Extends at Least Two Decades Caitlin E. Cox September 06, 2019
News Conference News ESC 2019 Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS Michael O'Riordan September 01, 2019
News Conference News ESC 2018 Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE Shelley Wood August 26, 2018
News Conference News ESC 2018 MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis Todd Neale August 26, 2018
News Conference News ESC 2017 COMPASS Charts New Course for Rivaroxaban in Stable Vascular Disease Todd Neale August 27, 2017
News Conference News ESC 2016 Ezetimibe Plus Pitavastatin Fails to Lower Risk of CVD Events in ACS Patients: HIJ-PROPER Michael O'Riordan August 30, 2016
News Conference News ESC 2016 Platelet Function Testing to Guide Treatment Does Not Benefit Elderly ACS Patients: ANTARCTIC Todd Neale August 28, 2016
News Conference News RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets August 31, 2011